Literature DB >> 11413775

The Jeremiah Metzger Lecture. Hypercoagulable states: challenges and opportunities.

R L Nachman1.   

Abstract

Thromboregulatory physiology is essentially a function of the blood vessel wall. Constitutive endothelial cell activities maintain blood fluidity by down regulating the initiation as well as, the propagation of blood coagulation. The major systems involved include: the Protein C, TFPI, plasmin generating and antithrombin pathways, all of which are focused on the cell membrane. Altered regulation of these endothelial functions forms the basis of the pathophysiologic events associated with the inherited primary hypercoagulable states. Secondary hypercoagulable syndromes occurring in various clinical states with conversion to a vascular thrombogenic phenotype reflect non constitutive activated endothelial cell functions with concomitant down regulation of the constitutive anticoagulant surface activity. So called idiopathic clinical thrombosis in most circumstances represents multi hit events in which specific genetic abnormalities or polymorphisms together with specific acquired alterations in geographically distinct endothelial cell beds culminate in a recognizable coagulation phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413775      PMCID: PMC2194424     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  50 in total

1.  Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.

Authors:  E Thorelli; R J Kaufman; B Dahlbäck
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

Review 2.  Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC resistance) causes hypercoagulability by dual mechanisms.

Authors:  B Dahlbäck
Journal:  J Lab Clin Med       Date:  1999-05

3.  Hyperhomocysteinemia and venous thrombosis: a meta-analysis.

Authors:  M den Heijer; F R Rosendaal; H J Blom; W B Gerrits; G M Bos
Journal:  Thromb Haemost       Date:  1998-12       Impact factor: 5.249

4.  Geographic distribution of the 20210 G to A prothrombin variant.

Authors:  F R Rosendaal; C J Doggen; A Zivelin; V R Arruda; M Aiach; D S Siscovick; A Hillarp; H H Watzke; F Bernardi; A M Cumming; F E Preston; P H Reitsma
Journal:  Thromb Haemost       Date:  1998-04       Impact factor: 5.249

5.  Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide.

Authors:  D Pruefer; R Scalia; A M Lefer
Journal:  Gen Pharmacol       Date:  1999-12

Review 6.  Thrombosis in pregnancy: maternal and fetal issues.

Authors:  I A Greer
Journal:  Lancet       Date:  1999-04-10       Impact factor: 79.321

7.  Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats In vivo.

Authors:  N P Dudman; S E Temple; X W Guo; W Fu; M A Perry
Journal:  Circ Res       Date:  1999-03-05       Impact factor: 17.367

Review 8.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

Review 9.  Modulation of annexin II by homocysteine: implications for atherothrombosis.

Authors:  K A Hajjar; A T Jacovina
Journal:  J Investig Med       Date:  1998-10       Impact factor: 2.895

10.  Increased frequency of genetic thrombophilia in women with complications of pregnancy.

Authors:  M J Kupferminc; A Eldor; N Steinman; A Many; A Bar-Am; A Jaffa; G Fait; J B Lessing
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

View more
  1 in total

1.  Endothelial cell culture: beginnings of modern vascular biology.

Authors:  Ralph L Nachman; Eric A Jaffe
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.